Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Boundless Bio, Inc. - Common Stock (NQ:BOLD)

2.700 +0.250 (+10.20%)
Streaming Delayed Price Updated: 9:30 AM EDT, Jun 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 173,421
Open 2.710
Bid (Size) 2.700 (500)
Ask (Size) 2.710 (300)
Prev. Close 2.450
Today's Range 2.690 - 2.710
52wk Range 0.9612 - 2.790
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These stocks are moving in today's session ↗
Via Chartmill
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill

Performance

YTD
+121.3%
+121.3%
1 Month
+87.5%
+87.5%
3 Month
+148.8%
+148.8%
6 Month
+125.0%
+125.0%
1 Year
+167.3%
+167.3%

More News

Read More
News headline image
BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
The market is filled with gapping stocks in Tuesday's session. ↗
Via Chartmill
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
From Boundless Bio, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies
Via Investor Brand Network
Topics Artificial Intelligence
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
Via Investor Brand Network
News headline image
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Tuesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio to Participate in the Leerink Global Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio (BOLD) Q2 R&D Drops 17% ↗
Via The Motley Fool
News headline image
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Announces Portfolio Prioritization and Runway Extension
From Boundless Bio, Inc.
Via GlobeNewswire
News headline image
Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights
From Boundless Bio, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Boundless Bio, Inc. - Common Stock publicly traded?
Yes, Boundless Bio, Inc. - Common Stock is publicly traded.
What exchange does Boundless Bio, Inc. - Common Stock trade on?
Boundless Bio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Boundless Bio, Inc. - Common Stock?
The ticker symbol for Boundless Bio, Inc. - Common Stock is BOLD on the Nasdaq Stock Market
What is the current price of Boundless Bio, Inc. - Common Stock?
The current price of Boundless Bio, Inc. - Common Stock is 2.700
When was Boundless Bio, Inc. - Common Stock last traded?
The last trade of Boundless Bio, Inc. - Common Stock was at 06/30/26 09:30 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.